19 patents currently held
86 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next term ends in Aug 2027. from the record
Of the 86 now held by other companies, 21 name CommScope Czech Republic S R O as their current owner, and 65 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Aug 2027
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2035 · High confidence
Also notable
Ends Aug 2028 · High confidence
Also notable
Ends no later than Aug 2027 · Low confidence
Pyrrolobenzodiazepine-Antibody Conjugates
US 9,931,414
Cited by 51 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Polynucleotides and Polypeptide Sequences Involved in Cancer
US 8,216,582
Cited by 39 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
System for Monitoring an Area Adjacent a Vehicle
US 11,603,042
A family of 11 related applications built on the 2023 grant. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends Apr 2034 · Medium confidence
Cited by 27 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
now held by CommScope Czech Republic S.R.O.
Also notable
Ends Jan 2034 · High confidence
Cited by 62 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Also notable
Ends Jan 2027 · Medium confidence
Cited by 53 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2027.
now held by CommScope Technologies LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for RFID-Enabled Optical Adapter for Use with a Patch Panel (US 9,052,472) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
- 2 fees due Jan 4 to 18, 2027 · next Jan 4
- 1 fee due Mar 19, 2027The maintenance fee for Seat Cover for Linearly-Tufted Automobile Seats (US 11,760,241) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof (US 10,597,450) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for ANTI-IL13R ALPHA2 Antibodies (US 11,976,122) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
- 9 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Polynucleotides and Polypeptide Sequences Involved in Cancer | 4 in force | to Mar 2032 |
| PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates | 2 in force | to May 2038 |
| Pyrrolobenzodiazepine-Antibody Conjugates | 1 in force | to Jun 2040 |
| Seat Cover for Linearly-Tufted Automobile Seats | 1 in force | to May 2039 |
| Site-Specific Antibody-Drug Conjugates | 1 in force | to Mar 2037 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,603,042 | System for Monitoring an Area Adjacent a Vehicle held by ADC Solutions Auto, LLC In force · Low confidence | In force | Low confidence | |
| US 8,216,582 | Polynucleotides and Polypeptide Sequences Involved in Cancer held by ADC Therapeutics S.A. In force · High confidence | In force | High confidence | |
| US 8,934,666 | Method and Device for Analyzing Surrounding Objects And/Or Surrounding Scenes, Such as for Object and Scene Class Segmenting In force · High confidence | In force | High confidence | |
| US 8,657,504 | Optical Fiber Connection Device Having a Rotating and Fixing Mechanism and Positioning Member In force · High confidence | In force | High confidence | |
| US 8,937,163 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof held by ADC Therapeutics S.A. In force · High confidence | In force | High confidence | |
| US 9,393,302 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof held by ADC Therapeutics S.A. In force · Medium confidence | In force | Medium confidence | |
| US 10,597,450 | Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof held by ADC Therapeutics S.A. In force · Medium confidence | In force | Medium confidence | |
| US 9,448,370 | Connector and Connector Assembly In force · High confidence | In force | High confidence | |
| US 9,052,472 | RFID-Enabled Optical Adapter for Use with a Patch Panel In force · High confidence | In force | High confidence | |
| US 11,690,918 | PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates held by ADC Therapeutics S.A. In force · High confidence | In force | High confidence |
Also on record, not counted in the 19: 86 patents in force now held by others · 263 patents ended · 9 applications pending · 119 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.